Gaming

Son Myeon-seok, CEO of Wemade Max: "Our Development Direction Remains Unchanged Despite Change in Largest Shareholder"

First Internal Message Following News of a Change in Wemade Co., Ltd.’s Largest Shareholder "The Group's Core Development Organization Is Set to Play a Greater Role" Continued Development of New Titles Such as 'Night Crow W' and 'Mir 5'

An Yu-ri
2026-07-01 16:53:00
[Edaily Reporter An Yu-ri ] As Wemade Co., Ltd.(112040)prepares for a change in its largest shareholder following Chairman Park Kwan-ho’s sale of his entire stake, Son Myeon-seok, CEO of Wemade Max, sent an internal message to employees stating, “Our development direction will not change.”

This is interpreted as an effort to quell organizational anxiety stemming from the change in the largest shareholder and to demonstrate the company’s commitment to continuing its role as the group’s core development organization.

Son Myeon-seok, CEO of Wemade Max (Photo: Wemade Max)

According to the gaming industry on the 1st, CEO Son stated in an internal notice sent to employees that day, “Changes in the corporate governance structure at the level of the parent company’s largest shareholder are significant for the company,” but added, “What Wemade Max must do remains unchanged, and we will assume an even more important role within the group.”

CEO Son emphasized, “We have competed based on our development capabilities and execution skills even amid market changes, and we have built user trust through high-quality games,” adding, “The development capabilities and service experience we have accumulated through this process are Wemade Max’s greatest competitive advantage, one that will not be easily shaken by any changes in the external environment.”

He stressed, “Not only are we ensuring the stable operation of our currently live games, but the development of major new titles is also proceeding smoothly as planned, and there is no change in the company’s development direction.”

This message marks the first official internal statement from a CEO of a group affiliate since the Chinese investment firm NeoPulse decided to acquire a 39.33% stake held by Wemade Co., Ltd. Chairman Park Kwan-ho.

CEO Son interpreted this change in corporate governance as “a process of laying the groundwork for Wemade Co., Ltd. to expand into larger markets.”

In particular, he noted, “Coincidentally, yesterday brought the meaningful news that ‘Night Crow’ received its Chinese publishing license,” adding, “Our long-prepared strategy for the Chinese market is being realized step by step, and we expect this momentum to steadily lead to global success in the future.”

Currently, Wemade Max is developing key projects such as ‘Night Crow W,’ ‘Mir 5,’ and ‘Project Tal,’ and plans to continue serving as the group’s core development pillar by simultaneously stabilizing live services and developing new titles.

CEO Son remarked, “There will continue to be various changes and new opportunities ahead,” adding, “Ultimately, it is our development capabilities and execution that will turn those opportunities into reality.”

He continued, “Wemade Max will steadfastly pursue our path toward the goal of becoming a globally recognized game developer,” adding, “We will ensure the robust growth of our live games and focus even more on developing our next projects to prove our competitiveness through results.”

Economy

Corporation

IT·Science

Economy

[Credit Checkpoint] Faded Strong Earnings… SAMYANG PACKAGING: Cash Reserves Dry Up, Debt Rises

“Credit Checkpoint” is a column that assesses the credit rating risks of companies preparing to issue corporate bonds by examining their financial structure and cash flows. We evaluate a company’s sho…
2026-08-27 16:02:05

Corporation

"Sought 44.3 Billion but Had to Return 1.1 Billion": Hong Won-sik, Former Chairman of Namyang, Loses Lawsuit

Hong Won-sik, former chairman of NamyangDairyProducts, lost his lawsuit against NamyangDairyProducts(003920)seeking 44.35775 billion won in severance pay. The court dismissed Mr. Hong’s claim for seve…
2026-08-27 15:08:45

IT·Science

Rigacem’s “Conjuol”-Based Anticancer Drug Granted FDA Fast Track Designation… Clinical Trials Expected to Accelerate

SOTIO Biotech, a partner company of LigaChem Biosciences(141080), announced on the 27th that SOT106, an antibody-drug conjugate (ADC) currently under development, has been granted Fast Track designati…
2026-08-27 16:22:02